Advanced Wound Dressing Patents: Leaders, Trends & White Space 2026
- A shallow, concentrated ranking. the leading assignee holds 10 records against a fifth-place count of just 2, with only nine companies appearing in the ranking at all.
- Two IPC classes carry the field. A61F (implants & prostheses) and A61L (sterilising & disinfecting) each cover 60.9% of the 23 records in scope — everything else sits below 9%.
- Filing peaked in 2019, then went quiet. the trend ran from zero in 2017 to a high of 10 in 2019, with 2026 activity still partial under normal publication lag.
What this dataset covers
This landscape tracks patent families and published applications matching advanced wound dressing and alginate wound dressing language, filtered to documents that specifically discuss absorption capacity, moisture vapour transmission, adherence to the wound bed, wear time, antimicrobial silver, or conformability. That combination narrows the set to 23 records published between 2015 and mid-2026, weighted toward exudate-handling mechanics rather than wound care broadly.
The scope is intentionally tight: it is not general wound-care IP, but the subset where dressing performance claims are argued on physical or biochemical grounds. That makes the ranked assignees and cited records below a reasonable proxy for who actually contests these mechanisms in claims language, rather than who simply markets a wound-care brand.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 23-record set: when filings happened, and which IPC subclasses carry the technical substance.
A single peak year, then a drop-off
Filings in scope moved from zero in 2017 to a peak of 10 in 2019, the busiest year this dataset records. Activity has not returned to that level since, and 2026 shows only 1 record so far — expected, since publication lags filing by roughly 18 months and the most recent year is always undercounted.
Two classes dominate, the rest are thin
A61F and A61L each appear on 60.9% of the 23 records in scope, meaning most dressings in this set are claimed simultaneously as a physical implant/prosthesis structure and as a sterilising/disinfecting mechanism. Every other class — A61K, A61B, A61P, C08B, C08F, C08J — sits at or below 8.7%, meaning the polymer chemistry and formulation side of exudate management is comparatively lightly claimed.
Shares are the percentage of the 23 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Advanced Wound Dressings and Exudate Management with Eureka
This page is one run against one query. Ask Eureka your own question about advanced wound dressings and exudate management and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this set
Super-absorbent advanced wound dressing with dressing full indication
A wound dressing includes a hydrophilic foam layer, a drape layer, superabsorbent projections, and printed indicators. The hydrophilic foam layer engages the wound bed; the drape layer sits over it; non-contiguous superabsorbent projections extend from the foam toward the drape; and printed indicators surround the projections to visually signal saturation.Filed by Solventum Intellectual Properties Company, published 2021-12-30 as US20210401627A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20200093646A1 | Super-absorbent, low trauma, advanced wound dressing | 32 |
| 2 | US6809231B2 | Flexible and absorbent alginate wound dressing | 23 |
| 3 | WO2020014310A1 | Advanced wound dressing with compression and increased total fluid handling | 21 |
| 4 | US20030105419A1 | Flexible and absorbent alginate wound dressing | 7 |
| 5 | WO2003045293A1 | Flexible and absorbent alginate wound dressing | 6 |
| 6 | US20230023873A1 | Collagen-arginate wound dressing material and method for producing same | 2 |
| 7 | US20210146002A1 | Unique combination of natural biopolymers for advanced wound dressing | 1 |
Citation counts are drawn from a searched corpus and favour older filings; treat them as a signal of influence on later claim drafting, not of current commercial importance.
Publication numbers are shown where the record carries one (7 of 7 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the ranking, the trend and the IPC composition are read together.
A shallow but real gap at the top
The leading assignee holds 10 records in this set while fifth place holds only 2, and the ranking itself lists just nine companies. That is a steep drop-off rather than a broad plateau, but with only 23 records total it does not support a concentration percentage — read it as evidence of one active leader, not market dominance.
Structure and sterility, not formulation
The two largest IPC classes both concern physical dressing structure and disinfection, each covering 60.9% of records. Formulation-side classes — polysaccharide chemistry (C08B), polymer processing (C08J), medicinal preparations (A61K) — each sit at 8.7% or below, suggesting claim space on the chemistry side is comparatively open.
Activity cooled after 2019
Filing volume peaked at 10 in 2019 and has not returned to that level; the latest year shows just 1 record, though publication lag means 2025–2026 filings are still arriving. The two most recent filers in this set, Nath Debjani and Mandal Sukanta, appear together as a co-assignee pair, the only fresh movement visible in recent-year data.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to advanced wound dressings and exudate management, with the prior art for and against each one.
Who is filing, and who has gone quiet
The ranking is short and top-heavy, with one working co-assignee relationship and almost no recent-year filing among the historical leaders.
One company well ahead of the rest
The top-ranked assignee's 10 records make it the only participant with a filing history broad enough to call a program rather than a single filing. Its recent-year momentum is 0, though, meaning its documented activity in this set is historical rather than current.
A licensing or corporate-structure link, not open collaboration
Only two co-assignee pairs exist in this dataset. The strongest links a wound-management specialist to a corporate co-owner across 3 records, which reads as a corporate or licensing structure rather than an active joint R&D program — there is no wider web of shared filings here.
New entrants, not incumbents, filed most recently
The only activity recorded in the latest year comes from two individual co-filers, Nath Debjani and Mandal Sukanta, each with one record. None of the historically larger assignees — the top-ranked company, the wound-management specialist, or the government filer — show any latest-year filings in this set.
| Assignee | Recent year | YoY |
|---|---|---|
| NATH DEBJANI | 1 | — |
| MANDAL SUKANTA | 1 | — |
| KCI Licensing, Inc. | 0 | — |
| P L MICROMED CO LTD | 0 | — |
| Government of the United States, as represented by the Secretary of Health and Human Services | 0 | — |
| SYSTAGENIX WOUND MANAGEMENT LTD | 0 | — |
| EDWARDS JUDSON V | 0 | — |
| Solventum Intellectual Properties Company | 0 | — |
Where to take this analysis
The dataset points to specific follow-up questions depending on whether the goal is freedom-to-operate, licensing, or new filing.
Check freedom-to-operate against the cited leaders
The five most-cited records, including the alginate wound dressing family cited 23 times, define the prior art that any new absorption-capacity or wear-time claim will be measured against.
Run a citation map in EurekaProbe the formulation-side white space
Polysaccharide and polymer-processing classes sit under 9% of records each, well below the structural and sterilising classes — a candidate area for a first claim rather than a design-around.
Explore IPC gaps in EurekaWatch the newest filers, not the historical leader
The only latest-year activity in this set comes from two individual co-filers rather than the top-ranked incumbent, which may signal where new claim language is being tested first.
Track assignee activity in EurekaCommon questions on advanced wound dressing patents
In this dataset the ranking is short — only nine companies appear at all — and one assignee leads clearly with 10 records against 2 at fifth place. That gap suggests one company built a sustained filing program in this specific technical niche (absorption capacity, moisture vapour transmission, silver antimicrobial, wear time and conformability) while everyone else filed a handful of records. It does not mean that company dominates the broader wound-care market, only that it dominates this narrowly defined claim space.
The two largest IPC subclasses in this set are A61F (implants and prostheses) and A61L (sterilising and disinfecting), each covering 60.9% of the 23 records in scope. Because a single patent can carry multiple IPC codes, these shares add up to well over 100% and should not be read as market share. Formulation-related classes such as A61K (medicinal preparations) and the polymer-chemistry classes C08B, C08F and C08J each appear on 8.7% or fewer records, indicating the chemistry side of exudate management is claimed far less densely than the structural and sterilising side.
Filing in this dataset peaked in 2019 at 10 records and has not returned to that level since, with the most recent complete years showing lower counts. A growth rate cannot be reliably computed from this evidence because fewer than four complete years remain once normal publication lag is accounted for, and 2026 data is still partial. Anyone tracking this space should expect the true 2025–2026 filing count to rise somewhat as those applications publish.
US20210401627A1, filed by Solventum Intellectual Properties Company and published in December 2021, describes a wound dressing built from a hydrophilic foam layer, a drape layer, and non-contiguous superabsorbent projections fixed to the foam and extending toward the drape. A distinguishing feature is printed indicators surrounding the projections, which visually signal when the dressing has reached capacity. Anyone designing a saturation-indicating superabsorbent dressing should review this filing's claim scope closely before finalising a similar visual-indicator mechanism.
The clearest gap sits in the formulation and polymer-chemistry classes — C08B (polysaccharides), C08F (addition polymers) and C08J (polymer processing) — each appearing on only one of the 23 records in scope, versus 14 records each for the two dominant structural and sterilising classes. That imbalance suggests claims built around novel absorbent-matrix chemistry or polymer-solution processing for dressing films face less crowded prior art than claims built around dressing structure or silver-based sterilisation, though a full freedom-to-operate search against the cited leaders is still necessary before filing.
Research Advanced Wound Dressings and Exudate Management in depth with Eureka
Go past this page: query the whole advanced wound dressings and exudate management corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.